Press Releases and Blog
Blog
InsideSources: JC Scott – Drug Companies: Lower the List Price
The Administration’s recent proposal on drug prices rightly recognizes that Americans are getting ripped off by paying higher drug prices than anyone in the world,
Drug Companies Should Lower Rx List Prices
JC Scott: “The sticker price, set solely by the drug company, decides the starting point for all PBM and drug company negotiations.” PCMA president and
PCMA Urges CMS to Protect Pharmacies in Medicare Fair Price Program
Under the Inflation Reduction Act (IRA), for designated drugs that are negotiated by CMS in Medicare Part D, the pharmacy is no longer paid by
ICYMI: Experts Discuss Value of PBMs at Capitol Hill Briefing
What exactly are pharmacy benefit managers (PBMs) and why are policymakers hearing so much about them now? That was one of the questions answered as
ICYMI: Experts Discuss Value of PBMs at Capitol Hill Briefing
What exactly are pharmacy benefit managers (PBMs) and why are policymakers hearing so much about them now? That was one of the questions answered as
PBMs Innovating to Increase Biosimilar Use, Lower Rx Costs
Big Pharma Continues to Undermine Competition, Setting High Drug Prices to Boost Profits As the House Ways and Means Subcommittee on Health today holds a
Press Releases
New Research from Phoenix Center Chief Economist Underscores Critical Cost-Saving Role of PBMs
White Paper from George S. Ford, Ph.D., Highlights How PBMs Drive Down Costs; Cautions Against Misguided Policies Undermining PBMs (Washington, D.C.) — The Pharmaceutical Care Management
PCMA Supports Bipartisan Solution to Empower Pharmacists, Improve Access to Respiratory Care for America’s Seniors
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement Tuesday on the introduction of The Ensuring Community Access to Pharmacist Services Act in
Updated Comprehensive Analysis from Leading Economists Confirms PBMs Deliver Value for Plan Sponsors, Support Pharmacies
PBMs Support Non-Affiliated Pharmacies, Provide Higher Reimbursement (Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on the release of an
PCMA Launches Campaign Urging Drug Companies to Lower the List Price
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) launched a new campaign today, “Lower the List Price,” a Beltway advertising campaign demanding drug
PCMA Statement On Drug Pricing Executive Order
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released a statement today following President Trump’s Executive Order on drug pricing. “America’s pharmacy benefit managers
PBMs Secure Savings for Patients and Employers in New Jersey
Misguided Policies will Raise Costs for Patients, Employers, and Unions (Trenton, NJ) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on the
InsideSources: JC Scott – Drug Companies: Lower the List Price
The Administration’s recent proposal on drug prices rightly recognizes that Americans are getting ripped off by paying higher drug prices than anyone in the world,
Drug Companies Should Lower Rx List Prices
JC Scott: “The sticker price, set solely by the drug company, decides the starting point for all PBM and drug company negotiations.” PCMA president and
PCMA Urges CMS to Protect Pharmacies in Medicare Fair Price Program
Under the Inflation Reduction Act (IRA), for designated drugs that are negotiated by CMS in Medicare Part D, the pharmacy is no longer paid by
ICYMI: Experts Discuss Value of PBMs at Capitol Hill Briefing
What exactly are pharmacy benefit managers (PBMs) and why are policymakers hearing so much about them now? That was one of the questions answered as
ICYMI: Experts Discuss Value of PBMs at Capitol Hill Briefing
What exactly are pharmacy benefit managers (PBMs) and why are policymakers hearing so much about them now? That was one of the questions answered as
PBMs Innovating to Increase Biosimilar Use, Lower Rx Costs
Big Pharma Continues to Undermine Competition, Setting High Drug Prices to Boost Profits As the House Ways and Means Subcommittee on Health today holds a
PCMA Congratulates Dr. Mehmet Oz on His Confirmation to Lead the Centers for Medicare & Medicaid Services
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released a statement today following the U.S. Senate confirmation of Dr. Mehmet Oz, M.D. to serve
PBMs Work to Lower the Costs of GLP-1 Drugs
PBMs are facilitating coverage of these drugs for weight management, but Big Pharma companies are still shifting blame for their high prices onto PBMs.
PBMs Are Breaking Down Barriers to Expand Access to Biosimilars and Lower Consumer Costs
While Drug Companies Drive Up Drug Prices with Anti-Competitive Behavior, PBMs Continue to Innovate and Lower Costs for Consumers As policymakers tackle America’s prescription drug
PBMs Offer Innovative Cost-Sharing Programs to Address Patient Out-of-Pocket Costs
Lowering Patient Costs Leads to More Accessible and Affordable Prescription Drugs More than 92% of prescriptions cost patients less than $20 at the pharmacy counter;
